After reprogramming of the somatic cells of patients with the familial form of 22q11.2 Deletion Syndrome into induced pluripotent stem cells (iPSCs), researchers of the STREAMLINE project are currently conducting the next phase of research – the differentiation of iPSCs into neurons and astrocytes. Neurons and astrocytes originating from patients with 22q11.2DS and healthy controls will be characterized and gene expression profiles will be analyzed by next-generation sequencing to discover sets of differentially expressed genes. These studies can contribute to the discovery of the pathophysiological mechanisms underlying this disease as well as the identification of new potential drugs in the future.
